Article Text

PDF
Management of antibiotic-resistant infection in the newborn
  1. James William Gray,
  2. Mitul Patel
  1. Department of Microbiology, Birmingham Women's Hospital, Birmingham, UK
  1. Correspondence to James William Gray, Department of Microbiology, Birmingham Women's Hospital, Edgbaston, Birmingham B15 2TG, UK; james.gray{at}bwhct.nhs.uk

Abstract

We are inexorably entering an era where a wide range of multiply antibiotic-resistant bacteria are commonplace. Until recently, multiresistance was mainly seen in Gram-positive bacteria. However, vancomycin remains adequate as a treatment of most infections with these bacteria. The potential threat from vancomycin-resistant bacteria has never fully materialised, and now there is a growing number of new anti-Gram-positive antibiotics. Of these, there is sufficient experience of using linezolid and daptomycin in neonates for these drugs to be recommended for some specific indications. The recent rapid international spread of multiresistant Gram-negative bacteria, including carbapenem-resistant strains, is much more ominous. Treatment options are extremely limited, which has prompted renewed interest in older and more toxic antibiotics such as colistin. However, the optimal management of serious neonatal infections with these bacteria remains to be determined.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.